The Proteases and Cancer Program has primarily been a basic science program that has successfully worked to integrate translational and preclinical research into the program during the past three years. The research efforts of this program have concentrated on four major questions: (1) how the tumor microenvironment, including tumor/host interactions, alters proteolysis and the impact of this on anti-protease therapies; (2) what are the mechanisms (gene to protein) that regulate activation and inhibition of proteases and how can these be used to develop more efficacious inhibitors or alternative anti-protease strategies for use in vivo; (3) how proteases and their endogenous inhibitors function in normal developmental and non-cancerous pathological processes with the goal of identifying new therapeutic targets; and (4) what are the critical proteases and their functions in cell death and differentiation, also with the goal of identifying new targets. Proteases of the five endopeptidase classes are currently under study in the Program or through inter-programmatic collaborations in the Cancer Center. In terms of protease inhibitors, program members are performing structure-function analyses on endogenous protease inhibitors (e.g., tissue inhibitors of matrix metalloproteinases, plasminogen activator inhibitor-1, maspin, and cystatins), designing and testing known and novel synthetic inhibitors for matrix metalloproteinases, cysteine (calpain and cathepsin) and aspartic proteases and exploring other interactions that may modulate protease-associated functions (e.g., galectin-3, HB-EGF, annexin II heterotetramer, caveolae). Translational research efforts are directed toward: 1) development of novel protease inhibitors as potential therapeutic agents, 2) determining whether interactions that may modulate protease-associated functions might serve as novel targets for therapeutic intervention, and 3) developing novel methods and probes for in vitro and in vivo imaging of protease activity. There are four collaborative subprograms to explore these research areas with considerable crossover and collaboration among the subprograms and other Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-25
Application #
7310828
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2005-12-01
Budget End
2006-11-30
Support Year
25
Fiscal Year
2006
Total Cost
$15,061
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Matherly, Larry H; Hou, Zhanjun; Gangjee, Aleem (2018) The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 81:1-15
Pollack, Murray M; Holubkov, Richard; Reeder, Ron et al. (2018) PICU Length of Stay: Factors Associated With Bed Utilization and Development of a Benchmarking Model. Pediatr Crit Care Med 19:196-203
Bao, Xun; Wu, Jianmei; Sanai, Nader et al. (2018) A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor. J Pharm Anal 8:20-26
Heath, Elisabeth I; Lynce, Filipa; Xiu, Joanne et al. (2018) Racial Disparities in the Molecular Landscape of Cancer. Anticancer Res 38:2235-2240
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47
McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177
McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging. Breast Cancer Res 20:130
Greenwald, Mark K; Ruterbusch, Julie J; Beebe-Dimmer, Jennifer L et al. (2018) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer :
Dyson, Greg; Farran, Batoul; Bolton, Susan et al. (2018) The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res 8:2088-2095
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963

Showing the most recent 10 out of 826 publications